Article

B&L finishes purchase of new fluoroquinolone

Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
Related Content
Pathways for better care: When patients and providers move in sync
June 18th 2025

Pathways for better care: When patients and providers move in sync

Commercial real estate and your practice, part two with Colin Carr
May 21st 2022

Commercial real estate and your practice, part two with Colin Carr

Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform
April 13th 2025

Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
May 12th 2022

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

How COVID-19 shifted ophthalmologist-patient communication
March 21st 2025

How COVID-19 shifted ophthalmologist-patient communication

AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire
October 17th 2024

AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire

© 2025 MJH Life Sciences

All rights reserved.